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Abstract
Background: We have previously shown that serum/glucocorticoid regulated kinase 1 (SGK1) is down-regulated in
colorectal cancers (CRC) with respect to normal tissue. As hyper-methylation of promoter regions is a well-known
mechanism of gene silencing in cancer, we tested whether the SGK1 promoter region was methylated in colonic tumour
samples.
Methodology/Principal Findings: We investigated the methylation profile of the two CpG islands present in the promoter
region of SGK1 in a panel of 5 colorectal cancer cell lines by sequencing clones of bisulphite-treated DNA samples. We
further confirmed our findings in a panel of 10 normal and 10 tumour colonic tissue samples of human origin. We observed
CpG methylation only in the smaller and more distal CpG island in the promoter region of SGK1 in both normal and tumour
samples of colonic origin. We further identified a single nucleotide polymorphism (SNP, rs1743963) which affects
methylation of the corresponding CpG.
Conclusions/Significance: Our results show that even though partial methylation of the promoter region of SGK1 is present,
this does not account for the different expression levels seen between normal and tumour tissue.
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Introduction
The serum/glucocorticoid regulated kinase 1 (SGK1) is a
recently identified member of the AGC family of serine/threonine
kinases, which shares 50% similarity in its aminoacid sequence
with other members of the family such as Akt/PKB, PKA and
PKC-zeta [1]. Sgk1 was originally identified as an immediate early
gene induced in response to serum and glucocorticoid stimuli in
rat mammary tumour cells [1]. A number of other stimuli such as
growth pathway signalling factors [2,3], cytokines [4], hormones
[5,6,7,8] and stress conditions [9,10] have recently been found to
induce activation of Sgk1 transcription. Not surprisingly, over 40
potential transcription factor-binding sites have been predicted in
the promoter region of Sgk1 [11] and a number of functions have
been attributed to this kinase in recent years.
Its best-studied roles are perhaps in the control of ion transport.
In particular, SGK1 was shown to allow accumulation of the
epithelial sodium transport channel ENaC by phosphorylating its
ubiquitin ligase Nedd4-2 [12], thereby increasing Na
+ re-
absorption [13,14]. SGK1 was also shown to regulate K
+,C a
2+
and Cl
2 channels and glucose transporters such as GLUT1 and
SGLT1, probably resulting in regulation of cell volume and
osmolarity, although these mechanisms are not well understood at
present [14]. SGK1 was also found to affect the function of several
kinases and transcription factors, including GSK3b [15], B-raf
[16], components of the Erk signalling pathway [14], the cAMP
responsive element (CREB) [17] and the forkhead transcription
factor FKHRL1 (FOXO3a) [18]. Even though the outcome of
these interactions is unclear in most cases, SGK1 has been
implicated in the regulation of cell survival and apoptotic response
[18,19] and cell cycle progression [20]. Furthermore, its C. elegans
homologue has been implicated in the control of development,
stress response and longevity [21]. Not surprisingly then, SGK1
expression was found to be deregulated in several tumour types
(up-regulated in breast cancers [10,19] and down-regulated in
prostate cancers [22] and ovarian tumours [23]). However, no
information is available at present on how modulation of SGK1
expression in cancer is achieved.
We have previously shown that expression of SGK1 is down-
regulated in colorectal adenomas and carcinomas [24] in
comparison to normal tissue. As hypermethylation of promoter
regions has been shown to silence transcription [25] and to
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[26,27,28,29], we set out to investigate the methylation profile of
the SGK1 promoter region in colorectal cancer cell lines and in
normal and tumour colonic tissue samples.
Results
To investigate whether down-regulation of the SGK1 transcript
could be reversed in colorectal cancer cell lines, we treated the cells
with serum and the corticosteroid dexamethasone, both of which
have been previously reported to increase transcription of Sgk1
[5,15].
No significant increase in SGK1 expression levels was found
when the cells were treated with serum over a period of 5 days,
after serum starvation (data not shown). Upon dexamethasone
treatment, no significant increase in SGK1 expression was seen in
HT29, HCT116, RKO or LS174T cells after 1, 3 or 5 days,
compared to untreated control (t-test p-values between 0.1 and
0.3). The CRC cell line LOVO showed modestly increased levels
of SGK1 expression (3.7 to 6.2-fold), while the RIE-1 cell line,
which was used as a control as it is derived from normal small
intestinal cells of rat origin, showed a prominent increase in Sgk1
levels (average fold change=21; t-test p-value=1.2610
25)a s
expected from previous reports (Fig. 1a).
To confirm that the difference seen was not due to a lack of
glucocorticoid receptor (GR) in the CRC lines tested, we
investigated GR protein levels by western blotting, and showed
that the glucocorticoid receptor is abundantly expressed in all lines
tested (Fig. 1b).
Given these results, we reasoned that one of the possible
mechanisms responsible for the silencing of SGK1 transcription
could be hypermethylation of the promoter regions and we therefore
set out to investigate the methylation profile of the SGK1 promoter.
CpG islands methylation profiles
Since the promoter region of human SGK1 has not been
functionally characterized, we based our investigation on the CpG
islands identified by interrogation of the UCSC Human Genome
Browser. Two CpG islands close to the transcription start site were
identified and further investigated. Details are given in Materials
and Methods and Figure S1.
DNAs extracted from HT29, HCT116, RKO, LOVO and
LS174T colorectal cancer cell lines and the control proximal
tubule kidney cell line HK2 were investigated by bisulphite
conversion followed by cloning of the PCR products covering the
CpG island regions and sequencing of the clones. Results were as
follows.
CpG 1. Between 5 and 10 clones (median=8) were sequenced
for each cell line (average concordance between clones was 99%).
No methylation was found in the CpGs in this region in any of the
5 CRC cell lines or in the control cell line HK2. HK2 cells treated
with the CpG methyltransferase SssI were used as a positive
control and consistently displayed methylation of all CpGs in the
island.
CpG2. All CRC cell lines tested, as well as the positive
control, showed methylation of the CpGs in this region (between 8
and 10 clones were sequenced for each sample and average
concordance between the clones was 97%), however the untreated
control cell line HK2 did not (Figure 2).
To determine whether the methylation displayed by the CRC
lines is due to their transformed nature, or whether the difference
seen with respect to the control is attributable to tissue specificity,
we investigated the methylation status of the CpGs in this region in
a panel of DNAs extracted from 10 matched normal and tumour
human colonic tissue samples. Down-regulation of the SGK1
transcript was confirmed in all tumour samples by qRT-PCR
(Figure S2).
After bisulphite treatment and sequencing of a minimum of 5
clones for each sample, it was found that all tissue samples
(normals and tumours) displayed almost complete methylation of
the CpGs in this region (Figure 3). During our investigation, we
found that the 8
th CpG in this smaller island (chr6:134497925)
displayed a methylation pattern that varied among the cell lines
tested and was found to be unmethylated in HT29 and HCT116
Figure 1. SGK1 expression is not induced by glucocorticoids in colorectal cancer cells. A, fold change differences in SGK1 expression levels
upon Dexamethasone treatment, as measured by qRT-PCR relative to samples treated with vehicle only. The small intestinal rat cell line RIE-1 shows
significantly increased expression levels (p,0.001), whereas no significant change is detected in the colorectal cancer cell lines HT29, HCT116, RKO
and LS174T. Modestly increased levels (3.7 to 6.2-fold) of SGK1 expression were seen in the colorectal cancer cell line LOVO. B, representative western
blot of the glucocorticoid receptor protein, showing strong expression in all lines tested. Actin beta (ACTB) was used as a loading control.
doi:10.1371/journal.pone.0013840.g001
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in LOVO cells. Upon interrogation of the UCSC Genome
Browser, we found that the single nucleotide polymorphism (SNP)
rs1743963 is present at this position and we therefore designed
primers to the DNA sequence surrounding the SNP. Perfect
correspondence between the genotype of the cell lines at this SNP
and their methylation status for the 8
th CpG was found (Figure 4),
consistent with the fact that this polymorphism disrupts the CpG
by substituting the C allele with a T. We found HT29 and
HCT116 cells to be homozygous for the T allele at this locus,
RKO and LS174T cells to be heterozygous, while LOVO cells
were found to be homozygous for the C allele, in accordance with
the methylation patterns displayed.
Demethylation treatment
To confirm the data observed, we treated the same CRC cell
lines with 5-Aza-29-deoxycytidine (5-AzaC), an inhibitor of DNA
methylation, and assayed expression of SGK1 in treated and
untreated cells by qRT-PCR. As shown in Figure 5, treatment of
the cells with 5-AzaC resulted in a very small and statistically non
significant increase in SGK1 transcription levels (fold change
difference -1.5 to 1.4, t-test p-values$0.06), in accordance with the
finding that the main CpG island is unmethylated. Expression of
CDKN1A, which was previously shown to increase with 5-AzaC
treatment [30] and of CDKN2A, a gene known to be frequently
methylated in colorectal cancers [31], were used as positive
controls and showed increased transcription in most cell lines.
Discussion
We have previously reported down-regulation of the SGK1
transcript in colonic tumour tissue and colorectal cancer cell lines
with respect to normal tissue [24]. In the present study we have
shown that the down-modulation of SGK1 in colorectal cancer cell
lines cannot be relieved by stimulating the cells with serum or
Figure 2. The CpG2 island is methylated in colorectal cancer
cell lines. The dot diagrams report the methylation status at each of
the 25 CpGs in the CpG2 island as assayed by sequencing multiple
clones (between 8 and 10) from the colorectal cancer cell lines HT29,
HCT116, RKO, LOVO and LS174T and the control renal cell line HK2
(filled circle=methylated; white circle=unmethylated).
doi:10.1371/journal.pone.0013840.g002
Figure 3. Both normal and tumour colonic tissue samples display methylation at sites in CpG2 island. The dot diagrams report the
methylation status at each of the 25 CpGs in the CpG2 island as assayed by sequencing multiple clones (n=5) from matched normal (left panels) and
tumour (right panels) samples from 10 patients (filled circle=methylated; white circle=unmethylated).
doi:10.1371/journal.pone.0013840.g003
SGK1 Promoter Methylation
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13840glucocorticoids, both of which are known inducers of SGK1
transcription, suggesting that SGK1 is actively repressed in
colorectal cancer cells.
As hyper-methylation of promoter regions is a well known
mechanism of gene inactivation and suppression of gene
expression, we investigated whether it was responsible for the
lowered expression of SGK1 in colorectal tumours. The human
SGK1 promoter has not been functionally characterized, but two
CpG islands are found close to the transcription start site (TSS).
We initially investigated the methylation profile of all 151 CpGs
contained within these two regions by sequencing several clones of
the PCR products from bisulphite-treated DNA from 5 colorectal
cancer cell lines (HT29, HCT116, RKO, LOVO and LS174T).
No methylation was found at any of the 126 CpGs present in the
island most proximal to the TSS, which we named CpG1, in any
of the CRC cell lines tested. On the contrary, all CpG sites in the
island found further upstream of the TSS (CpG2), were found to
be methylated in all CRC cell lines, but not in the kidney-derived
control cell line HK2. DNAs extracted from colonic tissues of both
normal and tumour origin also displayed methylation of the CpG
sites in this region, suggesting that the difference seen between the
CRC cell lines and the control cell line HK2 is probably
attributable to the different requirements for SGK1 expression in
different tissues. SGK1 is known to play an important role in renal
electrolyte excretion [32] and it is plausible that higher expression
levels, or possibly the expression of different isoforms, are required
in the kidneys than in the intestinal tract, which would explain the
differences seen in the methylation patterns of the promoter
region.
Further confirmation that down-regulation of SGK1 in tumour
samples is not highly dependent on promoter hypermethylation,
was obtained by treating the CRC cell lines with 5-AzaC, an
inhibitor of methylation. qRT-PCR results show that the increase
in SGK1 expression levels following demethylating treatment is
small and non statistically significant, in accordance with the
finding that the promoter region of the gene is unmethylated for
the most part. SGK1 transcript levels were not found to be highly
increased even when 5-AzaC treatment was followed by
dexamethasone treatment (data not shown), suggesting that
stimulus-dependent induction of SGK1 expression is also not
greatly affected by methylation of the CpG2 island.
In addition we have found that the rs1743963 SNP affects the
methylation status of the corresponding CpG. The significance of
this data point is currently unknown. We could not find a direct
correlation between the genotype of this SNP and levels of SGK1
expression in the cell lines. However, it cannot be excluded that
the presence of this SNP plays a role in the regulation of SGK1
expression, for example through modulation of the binding of
specific transcription factors in the region. As expression of SGK1 is
highly stimulus-dependent, such effects may only become apparent
when the appropriate stimulus is applied to the cells.
In conclusion, our study shows that only the smallest of the two
CpG islands present in the promoter region of SGK1 is methylated
in colonic tumour tissues and cell lines. However, this region was
also found to be methylated in normal colonic tissue and therefore
is unlikely to account for the differences in SGK1 expression seen
between normal and tumour tissue samples, which are instead
most likely due to transcriptional repressors acting on the SGK1
promoter. What these repressors are and how they are controlled
remains to be defined.
Materials and Methods
We have worked solely on anonymised samples. Study of these
has been approved by Oxfordshire REC B 05/Q1605/66 and
covers this study. Patient consent is not required since we cannot
link molecular data back to the patient, however verbal informed
consent was obtained from all patients anyway.
Cell culture and dexamethasone treatment
The colorectal cancer (CRC) cell lines HT29, HCT116, RKO,
LOVO and LS174T were sourced as previously published [33]
and were grown in DMEM containing 10% foetal calf serum. The
rat RIE-1 small intestinal cell line [34] was grown in RPMI
medium with 10% foetal calf serum. The human proximal tubule
kidney cell line HK2 was purchased from the American Type
Figure 4. Correlation between genotype at SNP rs1743963 and methylation. Upper panels show representative images of the
electropherograms obtained from sequencing the region surrounding the rs1743963 SNP in each of the CRC cell lines tested. Below each
electropherogram is a summary of the methylation pattern found in the clones sequenced after bisulphite treatment of DNA (filled
circle=methylated; white circle=unmethylated).
doi:10.1371/journal.pone.0013840.g004
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medium supplemented with EGF and Bovine Pituitary Extract and
was chosen as a control given the unavailability of human normal-
like intestinal cell lines and the abundance of SGK1 transcript in
HK2 cells. All lines were maintained at 37uC and 5% CO2.
For dexamethasone treatment, cells were plated out and left to
grow to about 80% confluence. Following serum starvation for
24 hours, fresh serum-free medium supplemented with 1 mM
dexamethasone (Sigma) was added to the cells. Cells were assayed
1, 3 and 5 days after treatment.
qRT-PCR
RNAs were extracted from cell pellets with the GenElute
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich), according
to manufacturer’s protocol. RNAs were converted to cDNA using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), according to manufacturer’s instructions. TaqMan
Gene Expression Assays (Applied Biosystems) were used for SGK1
(Hs00178612_m1; Rn00570285_m1), CDKN1A (Hs00355782_m1)
and GAPDH(Hs99999905_m1; Rn99999916_s1), which was used as
an endogenous control for normalization. qRT-PCR was performed
on the ABI 7900HT (Applied Biosystems) according to manufac-
turer’s instructions and data were analysed with the comparative Ct
method, as described in Applied Biosystems’s User Bulletin No. 2.
GR western blot
Protein lysates were extracted from cultured cells, run on SDS-
page and blotted using standard methods. Blotted membranes
were blocked in 5% milk and incubated overnight with rabbit
polyclonal anti-glucocorticoid receptor antibody (Abcam, ab3579-
50, 1:400). Then further washed and incubated with HRP-
conjugated polyclonal goat anti-rabbit antibody (Dako, P0448)
and detected by chemiluminscence (ECL kit, GE Healthcare).
HRP-conjugated anti actin-beta antibody (Abcam, ab8226,
1:10000) was used as loading control.
DNA extraction (tissues and cell lines)
DNAs were extracted from fresh cell pellets using the DNeasy
Blood and Tissue Kit (QIAGEN), according to manufacturer’s
protocol.
Normal and tumour tissue samples were obtained from 10
patients undergoing colic resection, after verbal informed consent
had been taken. The samples were snap-frozen after resection.
Tissue sections were cut from the frozen specimens and stained
with haematoxylin and eosin. DNA was extracted from macro-
dissected areas of normal and tumour epithelium with the DNeasy
Blood and Tissue Kit (QIAGEN), according to manufacturer’s
protocol.
CpG methyltransferase treatment
DNA extracted from the HK2 cell line was treated with CpG
methyltransferase SssI (NEB), according to manufacturer’s proto-
col, purified by phenol/chloroform precipitation and used as a
positive control. Untreated DNA from the same cell line was used
as negative control.
Bisulphite treatment
The DNA Methylation Kit (ZYMO RESEARCH) was used for
bisulphite treatment of DNA samples, according to manufacturer’s
protocol. All reactions were performed in triplicates and pooled for
increased yield.
Choice of CpG regions, PCRs and primers
Two CpG islands were identified close to the transcription start
site (TSS) of SGK1 by interrogation of the UCSC Human Genome
Browser. The CpG island most proximal to the TSS, which we
named CpG1 (chr6:134495940-134496958), extends over
1019 bp and encompasses 126 CpGs. The second island (CpG2,
chr6:134497537-134497756) is 220 bp long and contains 25
CpGs. Figure S1 represents the position of the CpG islands with
respect to the TSS. Primers were designed to amplify the CpG
island regions from bisulphite-treated DNA, taking care not to
include any CpG in the primer sequence. The CpG1 region was
split into three overlapping PCRs, due to its size and the difficulties
in amplifying DNA after bisulphite treatment. Primer pairs were as
follows:
CpG1.1 forward 59-ttggttttggttaaaagtataaaaaa-39
CpG1.1 reverse 59-aataaaccaaacccccaac-39
CpG1.2 forward 59-ttgtttatgggggagatgt-39
CpG1.2 reverse 59-atccctacaaataccctctc-39
Figure 5. SGK1 expression upon 5-AzaC treatment. The bar chart shows relative fold changes in SGK1, CDKN1A and CDKN2A expression as
measured by qRT-PCR after treatment with the demethylating agent 5-AzaC. SGK1 expression levels are not significantly affected by demethylating
treatment (fold changes between 20.17 and 1.4), while expression of CDKN1A and CDKN2A is increased in most lines as expected (fold change
increases 1.7 to 2.7 and 2.2 to 297 respectively).
doi:10.1371/journal.pone.0013840.g005
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CpG1.3 reverse 59-cccttaacaacctcaattttca-39
CpG2 forward 59-gggattgtgttagatttagtaggtaa-39
CpG2 reverse 59-tcaaaactaccccaaaacttcttaa-39
Products were amplified using LA Taq (Takara Bio Inc).
Conditions are available upon request.
Cloning and sequencing
PCR products were cloned into the pGEMT vector, using the
pGEMTeasy kit (Promega), according to manufacturer’s protocol.
DNA was isolated from between 5 and 10 clones in each occasion,
using the QIAspin Miniprep Kit according to manufacturer’s
protocol, and used to PCR the inserted sequence with M13
primers (forward 59-GTTTTCCCAGTCACGAC-39, reverse 59-
CAGGAAACAGCTATGAC-39). After clean up with the QIA-
quick PCR Purification Kit (Qiagen), the PCR products were used
to perform a sequencing reaction, containing either the forward or
the reverse M13 primer and Big Dye Terminator mix (Applied
Biosystems). Sequencing reactions were run on an ABI3730 by the
Zoology Department at Oxford University. Conversion of
unmethylated cytosines was found to be 100% efficient. No new
sequence data were generated, therefore no deposit was made into
GenBank.
5-Aza-29-deoxycytidine (5-AzaC) treatment
Cells were plated out into 6-well plates and left to grow to 70%
confluency, at which point the medium was replaced with fresh
medium containing 0.5 mM 5-AzaC (Sigma). After 24 hours the
medium was replaced with fresh complete medium and the cells
were grown for a further 48 hours before assaying. Cells treated
with vehicle only served as controls.
Supporting Information
Figure S1 Schematic representation of the CpG islands
analyzed. The figure shows the position of the CpG islands
analyzed with respect to the transcription start site (TSS). The
filled (methylated) and white (unmethylated) circles represent each
individual CpG within the island. The arrows indicate the
direction of transcription (from right to left as the gene is on the
negative strand).
Found at: doi:10.1371/journal.pone.0013840.s001 (0.78 MB TIF)
Figure S2 SGK1 down-regulation in the primary tumour
samples. The bar chart reports relative fold changes of SGK1
expression in the primary tumour samples analysed, compared to
their matched normal tissue, as assayed by qRT-PCR. As
expected, all samples showed down-regulation of SGK1 (between
3- and 951-fold).
Found at: doi:10.1371/journal.pone.0013840.s002 (0.44 MB TIF)
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